These pathologically relevant findings represent the rationale which advocates the employment of tau-based strategies (Li and Gotz, 2017; Congdon and Sigurdsson, 2018) as promising disease-modifying intervention of slow progressing Alzheimer’s disease and other human dementias (Novak et al., 2018a; Jadhav et al., 2019), especially in view of the disappointing outcomes from Aβ-targeting pharmacological and immunological approaches (Sigurdsson, 2008; Giacobini and Gold, 2013; Doody et al., 2014; Salloway et al., 2014; Schroeder et al., 2016; Agadjanyan et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.